American multinational pharmaceutical and biotechnology company
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Pfizer has reported that its experimental drug sigvotatug vedotin did not improve survival in advanced non‑small cell lung cancer compared with standard therapy. The result setbacks expectations for a potential first‑in‑class antibody‑drug conjugate and follows Pfizer’s 2023 Seagen purchase.
The Pfizer-era office tower at 235 East 42nd Street is stabilized after beams buckled on the 21st floor. Evacuations have ended as investigators assess what caused the failure and how to prevent a collapse during the largest office-to-residential conversion in New York City.
Airbnb has purchased its first Manhattan office, a six‑story 42,500‑sq‑ft Beaux‑Arts building at 281 Park Avenue South for $81.5 million. The move accompanies a long-running clash with New York City over Local Law 18 restrictions on short-term rentals and signals a deeper commitment to the city with an employee hub for 600+ staff in the region.
Investigations have begun into the Midtown East building after columns buckled and bricks fell, triggering evacuations and a criminal inquiry. Inspections target firms connected to the 42nd Street conversion project and its safety practices.
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
Vivani Medical and Novo Nordisk are exploring a long-acting semaglutide implant to maintain weight loss, potentially replacing frequent injections. The device aims to release medicine steadily for months, pending clinical and regulatory validation.
The military is screening for low testosterone and offering therapy to qualified troops. Experts warn against overprescribing and emphasize that treatment targets those with clinically diagnosed deficiencies.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
A string of developments around testosterone replacement therapy (TRT) has sparked a national conversation. The US military is considering testing service members’ testosterone levels and expanding access to TRT where clinically appropriate, while lawmakers and experts weigh safety, ethics and performance implications. Reports from AP News, CNBC, CNBC and other outlets indicate a widening trend in how TRT is discussed and regulated.
The White House has convened a meeting with AI leaders to review a proposed cybersecurity framework for advanced models, following OpenAI's recent agent hacks and calls for greater government access. Attendees include executives from Hugging Face, Anthropic, and others; Meta and Alphabet may participate. Markets show mixed responses as investors watch the policy discussion unfold.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.